Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	81
Overall Study	STARTED	Mavrilimumab 30 mg	81
Overall Study	STARTED	Mavrilimumab 100 mg	85
Overall Study	STARTED	Mavrilimumab 150 mg	79
Overall Study	COMPLETED	Placebo	75
Overall Study	COMPLETED	Mavrilimumab 30 mg	77
Overall Study	COMPLETED	Mavrilimumab 100 mg	79
Overall Study	COMPLETED	Mavrilimumab 150 mg	74
Overall Study	NOT COMPLETED	Placebo	6
Overall Study	NOT COMPLETED	Mavrilimumab 30 mg	4
Overall Study	NOT COMPLETED	Mavrilimumab 100 mg	6
Overall Study	NOT COMPLETED	Mavrilimumab 150 mg	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01706926/flow